Phakic intraocular lenses (IOL) is projected to grow over the next decade due to increasing global prevalence of refractive errors (myopia and hyperopia), rapid advancements in lens technology and preference toward minimally invasive surgery/refractive error correction. They are a valid option without lens removal for individuals whose refractive errors are not treatable with laser vision correction.
The advent of biocompatible materials and improved lens engineering is paving way for safer range of such structures available to surgeons, and subsequently patients. The market is expected to expand at a compound annual growth rate (CAGR) of about 7.9%, during the forecast period, 2025 to 2035, the 2035 market value is predicted to be around USD 942.5 Million, whereas, the value in 2025 is registered as USD 440.6 Million.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 440.6 Million |
| Projected Market Size in 2035 | USD 942.5 Million |
| CAGR (2025 to 2035) | 7.9% |
Explore FMI!
Book a free demo
Phakic IOL market in North America has a prominent share, primarily owing to the enhanced preference for phakic lens implant surgeries and rising need for personalized medicine and targeted disease therapies in the region. The United States dominates North America.
The phakic IOL market in Europe is growing steadily propelled by a mature healthcare infrastructure along with a growing focus on advanced vision correction procedures. Market expansion is aided by the region's investment in research and development as well as supportive government grants.
Estimation for Asia-Pacific region to having highest CAGR during the forecast period owing to high prevalence of the refractive errors, increasing healthcare facilities, and rising healthcare cost. However, China is anticipated to grow during the forecast period due to the growing demand for vision correction.
Challenges
Surgical Risks, Limited Awareness, and High Cost of Procedures
Phakic intraocular lenses (IOL) market is challenged primarily through invasiveness and cost. In contrast to laser-based vision correction, phakic IOL implantation is a surgical process which demands highly proficient intervention by experienced ophthalmologists, with inherent risks of infection, irreversible endothelial cell mortality and cataract formation.
Moreover, patient awareness of SMILE is low compared to LASIK or PRK, particularly in developing regions where adoption of refractive surgery is not yet widespread. The high cost of procedures, along with their limited coverage by health insurance, also limit access, all the more so with young adults, who represent the biggest potential customer base.
Opportunities
Rising Myopia Prevalence, Cosmetic Preference, and Technological Advancements
Despite these challenges, evolving portfolio of phakic IOL market is growing at a rapid rate owing to increasing cases of moderate-to-high myopia in urbanized Asian populations especially. Phakic IOLs are an attractive option for patients with thin corneas or dry eye disease (are not candidates for corneal refractive surgery), given their reversible and high-definition nature.
Advances in lens materials, foldable IOL designs, and minimally invasive surgical techniques are accelerating opportunities. Demand is growing among appearance-conscious millennials, particularly for those who resist the long-term use of glasses or contact lenses.
Continued advances in toric phakic IOLs for astigmatism correction, individualized lens sizing with ocular imaging, and AI-enhanced surgical planning are likely to expand uptake even further. Long-term growth will be powered by elective vision correction markets in emerging economies, as awareness increases and prices stabilize.
Growth was subdued from 2020 to 2024 due to pandemic-related disruption of elective surgeries, but bounced back quickly as clinics resumed operations and demand for vision correction soared, particularly among screen-heavy lifestyles. A rise in contact lens rejection and fears of dry eye following LASIK were aiding in awareness of the phakic IOLs, as well.
Between 2025 and 2035, the high market share will belong to customizable IOLs with extended depth of focus, preloaded delivery systems, and digitally guided surgeries. Closer integration with ocular diagnostics, 3D imaging and biometric AI tools will decrease surgical risks and increase eligibility. Advancements in accessibility and global expansion will be further influenced by medical tourism and private ophthalmic centers.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | FDA and CE approvals for select IOL types |
| Consumer Trends | Interest from myopia patients ineligible for LASIK |
| Industry Adoption | Growth in specialty ophthalmology centers and refractive clinics |
| Supply Chain and Sourcing | Dominated by few global lens manufacturers |
| Market Competition | Few key players with premium offerings |
| Market Growth Drivers | Rising high myopia, dissatisfaction with contact lenses, and tech lifestyles |
| Sustainability and Environmental Impact | Minimal impact currently |
| Integration of Smart Technologies | Limited digital involvement |
| Advancements in Lens Materials | Use of collamer and hydrophobic acrylic materials |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Streamlined regulatory pathways for customized, AI-guided, and foldable phakic IOLs |
| Consumer Trends | Shift toward younger, active individuals seeking reversible vision correction |
| Industry Adoption | Mainstream adoption in multi-specialty hospitals and emerging market clinics |
| Supply Chain and Sourcing | Rise of regional OEMs, smart surgical kits, and digitized lens fitting platforms |
| Market Competition | Expansion of affordable alternatives, personalized lenses, and emerging regional players |
| Market Growth Drivers | Accelerated by non-invasive innovation, AI diagnostics, and private elective procedures |
| Sustainability and Environmental Impact | Shift toward recyclable surgical kits, reusable insertion tools, and green ophthalmic practices |
| Integration of Smart Technologies | Use of AI for lens sizing, surgical robotics, and cloud-linked outcome monitoring |
| Advancements in Lens Materials | Innovation in biocompatible polymers, hybrid toric-phakic lenses, and self-centering optics |
The market in the USA is expanding because of an increase in high myopia or corneas with thin corneas that require refractive surgery. Long-term alternatives to LASIK at custom phakic IOL packages with AI-driven diagnostics at private clinics. FDA approvals of newer lens types are giving physicians more options.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 8.0% |
In the UK, growing investment in private ophthalmic centres is providing superior access to premium vision correction procedures. Reversible, minimally invasive surgical options are trending, particularly among younger patients & professionals Next-gen IOL clinical trials being fueled by regulatory support for innovation
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 7.8% |
The EU market continues to grow, with better adoption of vision correction as an elective aspect of health packages, notably in Germany, France, and Spain. Toric and foldable phakic IOLs are rapidly adopted clinically, and research hospitals are essential testing facilities for AI-assisted lens customization platforms.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 7.9% |
One of the reason for increasing demand of phakic IOLs in Japan is high prevalence of severe myopia and cosmetic-driven, tech friendly population. Digitally guided implantation systems are being preferred by surgeons and miniaturized, pliable phakic lenses for outpatient use are under development by local suppliers.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 7.9% |
One of the fastest-growing markets is in South Korea, led by a sizable aesthetic surgery culture, a high number of advanced clinics, and government support for medical tourism. Custom-fitted, minimally invasive phakic IOL implants are experiencing a rise in demand particularly among young adult citizens who want for lifestyle and career-enhancing image improvement.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 8.1% |
The phakic intraocular lenses (IOLs) market is steadily growing as the demand for long-lasting refractive solutions increases among patients who are not good candidates for corneal refractive surgeries. Citing the advantage of a phakic IOL over traditional IOL used after cataract procedures, he explained that it is implanted without removal of the eye’s natural lens, thus making it a hallmark of high refractive errors.
Of the available types, posterior chamber phakic IOLs and the indication of myopia make up a commonly used segment of the market given their favorable anatomical compatibility, reduced surgical risk factors, and high volume demand. These divisions guarantee sound clinical results, rapid recuperation, and improved patient satisfaction during elective and therapeutic uses.
Continuing advancements in lens materials, design, and surgical techniques are broadening the availability of phakic IOLs as a corrective solution for young adults and patients with contraindications to LASIK or PRK. Posterior chamber lenses allow the most precise optical correction with the least risk to corneal health.
| Product | Market Share (2025) |
|---|---|
| Posterior Chamber Phakic IOL | 67.3% |
Posterior chamber phakic IOLs is expected to be the leading segment in the market with the maximum share, as they are placed behind the iris, in front of natural lens thus minimizing their contact with cornea as well as maintaining the physiological flow of aqueous humor. Use of these lenses aims to achieve excellent centration, high refractive precision, and long-term visual stability.
For their lower incidence of endothelial cell loss and lower incidence of glare and halos, and for the greater biocompatibility that they offer, surgeons prefer posterior chamber lenses. High myopes and patients with thin corneas or dry eyes are often excellent candidates for these lenses.
Manufacturers have improved on posterior IOL designs with foldable materials, UV-blocking filters and fittings made to measure with less risk for vaulting and ocular pressure problems. The minimally invasive implantation procedure can also encourage the use of the device in outpatient surgical centers.
Generally, although anterior chamber IOLs are placed quickly and do not require as much surgical sculpting, posterior chamber lenses are currently favored by most refractive ophthalmologists because of their outcomes and continued expansions in clinical guidelines.
| Indication | Market Share (2025) |
|---|---|
| Myopia | 70.2% |
Myopia correction dominates phakic IOL revenues as the prevalence of nearsightedness rises globally particularly among younger populations providing a strong initial impetus for permanent vision correction. Phakic IOL implantation is a reliable alternative to laser-based surgeries in those with high myopia that are not suitable for laser treatment.
Phakic IOLs for myopia provide better distance vision from sharper optics, quicker recovery, and less disruption to the cornea than other refractive options. They are particularly well-suited for patients with stable refractive errors and normal anterior chamber depth.
The growing popularity of phakic IOLs among ophthalmic practices is evident in that they have become increasingly favored in the 21-45 age group who are seeking refractive freedom, but are not yet candidates for presbyopia-correcting procedures.
The dominance in this segment is solidified by the high volume of treatment for myopia and its predictable outcomes. Phakic lens correction for hyperopia is still clinically feasible, but its clinical implementation is limited by anatomical considerations and a narrower indication range. In contrast, myopia is still the most common disorder treated with phakic IOLs worldwide.
The phakic intraocular lenses (IOL) market is projected to grow owing to the increasing revenue of refractive surgery centers, ophthalmic hospitals, and vision correction clinics. The increasing prevalence of high myopia and astigmatism, as well as demand for reversible and corneal tissue-sparing alternatives to LASIK, is making new lens designs for anterior and posterior chamber lenses attractive possibilities.
The industry is doubling down on foldable technology, toric phakic IOLs, and hybrid optics with enhanced biocompatibility. Surgical precision, long-term stability, and regulatory approvals are still focus topics for global manufacturers of ophthalmic devices and eye care specialists around the world.
Market Share Analysis by Key Players & Phakic IOL Manufacturers
| Company Name | Estimated Market Share (%) |
|---|---|
| STAAR Surgical Company | 14-18% |
| Johnson & Johnson Vision | 12-16% |
| Zeiss Group | 10-14% |
| EyeYon Medical | 8-12% |
| Nidek Co., Ltd. | 6-9% |
| Other IOL Manufacturers | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| STAAR Surgical Company | In 2024, expanded EVO Visian ICL availability with toric models across Asia-Pacific; in 2025, launched EVO+ ICL with blue-light filtering and enhanced optic zone for extreme myopia. |
| Johnson & Johnson Vision | Released its TECNIS® Phakic IOL in EU markets in 2024 targeting young adult myopia; in 2025, began clinical trials of adjustable phakic lenses with post-op light modulation features. |
| Zeiss Group | Introduced the Zeiss Clear View PC-IOL in 2024 with posterior chamber placement and anti-glare design; in 2025, added AI-enabled planning software for personalized IOL sizing. |
| EyeYon Medical | Launched the EndoArt™ platform in 2024 for combined corneal and lens procedures; in 2025, piloted a shape-adaptive phakic IOL for variable depth correction. |
| Nidek Co., Ltd. | In 2024, released high-diopter phakic IOLs for ultra-high myopia in select APAC markets; in 2025, upgraded injector systems to support minimally invasive lens delivery. |
Key Market Insights
STAAR Surgical Company (14-18%)
STAAR leads the global phakic IOL segment with its EVO platform. Its 2024 to 2025 innovations in optic zone expansion and toric correction reinforce its dominance in the reversible refractive surgery category.
Johnson & Johnson Vision (12-16%)
J&J is entering the phakic lens market with next-gen TECNIS® solutions. Its 2025 R&D on light-adjustable features positions it at the frontier of customizable post-op vision correction.
Zeiss Group (10-14%)
Zeiss combines optical engineering with software planning for optimized outcomes. The 2025 AI-based IOL sizing tools improve fit and visual quality across personalized posterior chamber lens procedures.
EyeYon Medical (8-12%)
EyeYon introduces dual-benefit ophthalmic implants, merging lens and corneal innovation. Its 2025 adaptive IOLs represent a novel class of shape-responsive, dynamic refractive correction.
Nidek Co., Ltd. (6-9%)
Nidek focuses on treating high refractive errors in underserved markets. Its 2024 to 2025 product suite supports efficient delivery and extreme myopia correction with surgical workflow compatibility.
Other Key Players (30-40% Combined)
Numerous ophthalmic companies are developing specialized IOLs with better material biocompatibility, customizable sizing, and minimally invasive delivery systems. These include:
The overall market size for the phakic intraocular lenses (IOL) market was USD 440.6 Million in 2025.
The phakic intraocular lenses (IOL) market is expected to reach USD 942.5 Million in 2035.
The demand for phakic IOLs is rising due to increasing cases of refractive errors, growing adoption of advanced vision correction procedures, and technological improvements in lens design. Rising preference for minimally invasive myopia correction and favorable clinical outcomes are further fueling market growth.
The top 5 countries driving the development of the phakic intraocular lenses (IOL) market are the USA, Japan, Germany, China, and South Korea.
Posterior chamber lenses and myopia correction are expected to command a significant share over the assessment period.
Protein Diagnostics Market Share, Size and Forecast 2025 to 2035
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Intraoperative Fluorescence Imaging Market Report - Demand, Trends & Industry Forecast 2025 to 2035
Lung Cancer PCR Panel Market Trends, Growth, Demand & Forecast 2025 to 2035
Polymyxin Resistance Testing Market Trends – Innovations & Growth 2025 to 2035
Phakic Intraocular Lenses (IOL) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
